hepatocellular carcinoma
Conditions
Interventions
observation group (Transarterial Therapies+TKI+ PD-1 Inhibitor):N/A
Sponsors
Zhujiang Hospital of Southern Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: (1) HCC was diagnosed according to the clinical diagnostic criteria of HCC in the Guidelines for Diagnosis and Treatment of Primary Liver Cancer (2022 Edition) or by pathology/cytology; (2) Patients with unresectable hepatocellular carcinoma (uHCC) considered surgically or oncologically; (3) Age =18 years old (4) Patients with stage B or C, or stage A BCLC with insufficient liver volume (liver without cirrhosis: SFLVR < 30%; Liver cirrhosis: SFLVR < 40%); (5)Child-Pugh Class A or B; (6)ECOG-PS score 0-1; (7) no serious heart, lung or renal dysfunction; (8) There is at least one measurable target lesion according to the modified mRESIST criteria for the evaluation of solid tumor efficacy.
Exclusion criteria
Exclusion criteria: (1) Concurrent with other active malignant tumors; (2) Have a history of allergy to any ingredients such as targeted drugs, chemotherapy drugs, immunotherapy drugs; (3) The expected survival time is less than 3 months; (4) Termination of treatment due to serious adverse reactions or abandonment of treatment; (5) Incomplete data.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| conversion surgrical rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective Response Rate;Disease Control Rate;Progression Free Survival;Overall Survival; | — |
Countries
China
Contacts
Public ContactMingxin Pan
Zhujiang Hospital of Southern Medical University
Outcome results
None listed